The FDA has approved AstraZeneca’s Fasenra (benralizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), a rare and serious inflammatory condition. The approval is based on positive results from a Phase 3 trial showing comparable efficacy and safety to the current standard treatment. Fasenra is now the second biologic approved for EGPA, providing a new option for patients battling this debilitating disease.